AYTU Aytu Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AYTU

Price (delayed)

$1.99

Market cap

$21.62M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.16

Enterprise value

$12.35M

?
Relative Growth: Rel. Growth: 38
Relative Strength: Rel. Strength: 30
Relative Valuation: Rel. Valuation: 35
Relative Profitability: Rel. Profitability: 24

Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT ® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) ...

Highlights
Aytu Biopharma's equity has surged by 86% YoY
AYTU's EPS has soared by 75% QoQ and by 46% YoY
The company's net income has surged by 58% QoQ but it fell by 5% YoY
Aytu Biopharma's quick ratio has decreased by 8% YoY but it has increased by 6% from the previous quarter
The gross profit has contracted by 20% YoY
AYTU's revenue is down by 13% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://aytubio.com
Peers: CGEM LQDT

Key stats

What are the main financial stats of AYTU

AYTU stock price

How has the Aytu Biopharma stock price performed over time
Intraday
1.02%
1 week
-2.93%
1 month
0%
1 year
-14.96%
YTD
-23.46%
QTD
-7.01%

Financial performance

How have Aytu Biopharma's revenue and profit performed over time
Revenue
$57.57M
Gross profit
$36.82M
Operating income
-$8.32M
Net income
-$14.25M
Gross margin
64%
Net margin
-24.8%
The company's net margin has surged by 59% QoQ but it fell by 22% YoY
The company's net income has surged by 58% QoQ but it fell by 5% YoY
Aytu Biopharma's operating margin has increased by 46% QoQ but it has decreased by 22% YoY
Aytu Biopharma's operating income has increased by 45% from the previous quarter but it has decreased by 6% YoY

Price vs fundamentals

How does AYTU's price correlate with its fundamentals

Growth

What is Aytu Biopharma's growth rate over time

Valuation

What is Aytu Biopharma stock price valuation
P/E
N/A
P/B
0.61
P/S
0.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.21
AYTU's EPS has soared by 75% QoQ and by 46% YoY
Aytu Biopharma's equity has surged by 86% YoY
The P/B is 39% below the last 4 quarters average of 1.0 but 22% above the 5-year quarterly average of 0.5
AYTU's P/S is 43% above its 5-year quarterly average of 0.3 and 8% above its last 4 quarters average of 0.4
AYTU's revenue is down by 13% YoY

Efficiency

How efficient is Aytu Biopharma business performance
The ROE has soared by 64% from the previous quarter but it has contracted by 12% YoY
AYTU's ROS has soared by 61% QoQ but it has shrunk by 51% YoY
The ROA has soared by 56% from the previous quarter but it has contracted by 9% YoY
Aytu Biopharma's ROIC has increased by 41% from the previous quarter

Dividends

What is AYTU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AYTU.

Financial health

How did Aytu Biopharma financials performed over time
Aytu Biopharma's total assets is 51% higher than its total liabilities
Aytu Biopharma's total liabilities has decreased by 34% YoY and by 9% QoQ
Aytu Biopharma's total assets has decreased by 15% YoY and by 6% QoQ
The company's debt is 52% lower than its equity
Aytu Biopharma's equity has surged by 86% YoY
The debt to equity has plunged by 58% YoY and by 23% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.